Drug

LTP001

Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry

Study Purpose

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial